Key result
Intravenous GPI before acute stenting fails to improve favorable 90-day functional outcomes.
Why the study?
The safety and efficacy of initiating glycoprotein IIb/IIIa inhibitor infusion prior to acute intracranial artery stent implantation needed evaluation.
Does intravenous glycoprotein IIb/IIIa inhibitor infusion prior to acute stent implantation improve 90-day functional outcomes and reduce perioperative stent thrombosis in patients with cerebral infarction?
Meta-Analysis (n=1,156)
Does intravenous glycoprotein IIb/IIIa inhibitor infusion prior to acute stent implantation improve 90-day functional outcomes and reduce perioperative stent thrombosis in patients with cerebral infarction?
Relative Risk: 1.14 (95% CI 1–1.3)
p-value: p=0.05
Intravenous GPI before acute stent implantation for cerebral infarction reduces perioperative stent thrombosis but does not significantly improve 90-day functional outcomes overall, though it may enhance outcomes in the carotid stenting subgroup.
Does not support routine intravenous GPI before acute cerebral stenting; confirms neutral effect on 90-day functional outcomes.
To evaluate the safety and efficacy of initiating glycoprotein IIb/IIIa inhibitor (GPI) infusion prior to acute intracranial artery stent implantation. We performed a meta-analysis using RevMan software to calculate the pooled risk ratio and 95% confidence intervals (CIs) to assess efficacy and safety. The systematic review and meta-analysis included 7 studies involving 1156 patients who underwent acute stent implantation. 1) Efficacy outcomes: GPI not significantly improved favorable 90-day functional outcome ( P = 0.05, I 2 = 0%, CI 1.14[1.00–1.30]). GPI significantly reduced perioperative stent thrombosis ( P < 0.00001, I 2 = 0%, CI 0.21[0.1–0.43]), the results did not indicate a significant advantage of GPI in recanalization ( P = 0.53, I 2 = 0%, CI 1.01[0.98–1.04]). 2) The findings showed that GPI did not result in a higher incidence of spontaneous intracerebral hemorrhage ( P = 0.76, I 2 = 0%, CI 0.93[0.59–1.48]), GPI not significantly improved favorable 90-day functional outcome in patients after stenting ( P = 0.05, I 2 = 0%, CI 1.14[1.00–1.30]). 3) Subgroup analysis: No statistically significant differences in recanalization (Thrombolysis in Cerebral Infarction ≥2b) ( P = 0.9, I 2 = 0%, CI 1.00[0.95–1.06]) and perioperative spontaneous intracerebral hemorrhage ( P = 0.77, I 2 = 5%, CI 1.50[1.01–2.22]) between the two groups, GPI was associated with a significant reduction in the incidence of perioperative stent thrombosis ( P = 0.0003, I 2 = 0%, CI 0.22[0.09–0.50]) and demonstrated an improvement in favorable clinical outcomes at 90 days after acute carotid stenting ( P = 0.04, I 2 = 1%, P = 0.001, CI 1.23[0.98–1.54]). The use of intravenous GPI before acute stent implantation can reduce perioperative intravascular thrombosis but does not improve patient outcomes at 90 days. The use of intravenous GPI before carotid acute stenting may enhance 90-day outcomes and reduce perioperative stent thrombosis.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) conducted a meta-analysis in Cerebral Infarction (n=1,156). Intravenous Glycoprotein IIb/IIIa Inhibitors vs. Control was evaluated on Favorable 90-day functional outcome (RR 1.14, 95% CI 1.00-1.30, p=0.05). Intravenous glycoprotein IIb/IIIa inhibitors before acute stent implantation did not significantly improve favorable 90-day functional outcomes (RR 1.14; 95% CI 1.00-1.30; P=0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: